Rithm Capital Corp. (RITM)
Live price chart, market sentiment, and community perspectives for Rithm Capital Corp. (NYSE: RITM).
Live price chart, market sentiment, and community perspectives for Rithm Capital Corp. (NYSE: RITM).
On our desk, we are looking closely at the valuation discrepancy. RITM is trading at 4.62X forward 12-month earnings, which sits miles below the 17.03X multiple for the broader Zacks sub-industry. However, you cannot ignore the rising cost pressures and higher expenses noted in the recent Q2 data. While the 12.2% monthly rally shows strong momentum, we are advising clients to weigh these operational friction points before chasing the upside.
From a risk management standpoint, the exposure to mortgage servicing rights and limited liquidity continue to cap our enthusiasm. Even though Newrez posted a massive 212% quarter-over-quarter earnings increase and Genesis achieved record originations, the macro environment around MSR volatility makes us keep a tight collar on our downside hedges.
As a hedge fund PM reviewing the Q2 2026 print, the real story here is the potential valuation rerating if RITM successfully transitions and is reclassified as an asset manager. With AUM surpassing $61 billion and fee-based growth accelerating, the fundamental thesis under $10 remains robust, supported by a secure 10%+ dividend yield and a 19.7% ROE.
As a quantitative analyst parsing the 10-Q highlights, the divergence between sell-side models and crowd sentiment is fascinating. Wall Street has 11 out of 11 buy ratings with an average target of $13.20, yet retail trackers record a neutral stance. We are monitoring the $10.36 pivot point to see if institutional accumulation will outpace the looming expense headwinds.
Watching the alternative data and sentiment indicators on my terminal, AltIndex gives RITM an AI Score of 55, classifying it strictly as a Hold. While web traffic and user growth metrics ticked up over the past 90 days, the lack of heavy retail chatter across X and Reddit suggests we are flying under the broader crowd radar while Wall Street maintains its unanimous 100% buy stance.
Explore plasma cleansing, somatic organ swaps, and BCI.